Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Registrational; Therapeutic Use
  • Acronyms VANISH 303
  • Sponsors SCYNEXIS

Most Recent Events

  • 01 Feb 2023 Results of pooled analysis assessing the effectiveness of ibrexafungerp in various patient subgroups that may impact outcomes in VANISH 303 (NCT03734991) and VANISH 306 (NCT03987620) were published in the Journal of Women's Health.
  • 03 Nov 2022 According to a SCYNEXIS media release, pooled results from VANISH-303 and VANISH-306 studies were peer-reviewed published in the Journal of Women's Health.
  • 03 Nov 2022 Pooled results from VANISH-303 and VANISH-306 studies presented in a SCYNEXIS media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top